JP2025527694A5 - - Google Patents
Info
- Publication number
- JP2025527694A5 JP2025527694A5 JP2025511613A JP2025511613A JP2025527694A5 JP 2025527694 A5 JP2025527694 A5 JP 2025527694A5 JP 2025511613 A JP2025511613 A JP 2025511613A JP 2025511613 A JP2025511613 A JP 2025511613A JP 2025527694 A5 JP2025527694 A5 JP 2025527694A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protein
- protein complex
- invariant region
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220105643 | 2022-08-23 | ||
| KR10-2022-0105643 | 2022-08-23 | ||
| KR20230057361 | 2023-05-02 | ||
| KR10-2023-0057361 | 2023-05-02 | ||
| PCT/KR2023/012348 WO2024043643A1 (ko) | 2022-08-23 | 2023-08-21 | Il2 변이체 및 이를 포함하는 단백질 복합체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025527694A JP2025527694A (ja) | 2025-08-22 |
| JP2025527694A5 true JP2025527694A5 (enExample) | 2025-09-19 |
Family
ID=90013668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025511613A Pending JP2025527694A (ja) | 2022-08-23 | 2023-08-21 | Ｉｌ２変異体及びそれを含むタンパク質複合体 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4578871A1 (enExample) |
| JP (1) | JP2025527694A (enExample) |
| KR (1) | KR102655850B1 (enExample) |
| CN (1) | CN119790064A (enExample) |
| AU (1) | AU2023330441A1 (enExample) |
| WO (1) | WO2024043643A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| AU2013258834B2 (en) * | 2012-05-10 | 2017-09-07 | Zymeworks Bc Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain |
| DK3186283T3 (da) * | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| AU2017213659B2 (en) * | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2017335771A1 (en) * | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
| EP3504234A4 (en) * | 2016-09-29 | 2020-12-02 | Beijing Hanmi Pharmaceutical Co., Ltd. | CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| MY201482A (en) * | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| IL275426B2 (en) * | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| JP2022554141A (ja) | 2019-10-25 | 2022-12-28 | オーデンツ セラピューティクス，インコーポレーテッド | 糖原病を治療するための組成物及び方法 |
| KR102559355B1 (ko) * | 2020-01-31 | 2023-07-25 | 주식회사 제넥신 | 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| CN118271419A (zh) * | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
| US20240034854A1 (en) | 2020-08-26 | 2024-02-01 | Reventas Limited | Improvements In Or Relating To Plastic Recycling |
-
2023
- 2023-08-21 JP JP2025511613A patent/JP2025527694A/ja active Pending
- 2023-08-21 WO PCT/KR2023/012348 patent/WO2024043643A1/ko not_active Ceased
- 2023-08-21 AU AU2023330441A patent/AU2023330441A1/en active Pending
- 2023-08-21 KR KR1020230109266A patent/KR102655850B1/ko active Active
- 2023-08-21 CN CN202380061464.0A patent/CN119790064A/zh active Pending
- 2023-08-21 EP EP23857675.5A patent/EP4578871A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220324931A1 (en) | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF | |
| JP2022105558A (ja) | 新規のポリペプチド | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| CN113226472A (zh) | 双免疫细胞衔接物 | |
| JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
| US20220098274A1 (en) | Engineered pd-1 variants | |
| JP2026053343A (ja) | 加齢性および炎症性疾患を治療する方法 | |
| CN105408356A (zh) | 双特异性构建体及其用于治疗多种疾病的用途 | |
| JP2024521405A5 (enExample) | ||
| JP2019058160A (ja) | ヒトｐ１８５及び血管内皮増殖因子の両方を標的とする抗体及びその適用 | |
| CN116981470A (zh) | T细胞调节多肽和其使用方法 | |
| US20130165629A1 (en) | Bispecific t-cell activator antibody | |
| JP2023541996A (ja) | ＳＩＲＰ１αキメラタンパク質の臨床投与 | |
| CN118946587A (zh) | 抗pd-1单克隆抗体及其衍生物和用途 | |
| WO2022200478A1 (en) | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor | |
| US20260085113A1 (en) | All-in-one agonistic antibodies | |
| CN113667004A (zh) | 一种白介素2突变体 | |
| Fellermeier-Kopf et al. | Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans | |
| JP2025527694A5 (enExample) | ||
| JP2023546269A (ja) | Ｔ細胞を増殖させるための二重特異性コンストラクトおよび関連する方法 | |
| JP2023527621A5 (enExample) | ||
| US20220175945A1 (en) | Antibodies and enonomers | |
| CN121646609A (zh) | Tnf超家族成员免疫细胞因子及其用途 | |
| CN118255899A (zh) | 一种IL2-IL2Rα异源复合物蛋白及其衍生物 | |
| Barragan-Galvez et al. | Prokaryotic expression of the immunoglobulin’s domains of CRTAM to characterize a monoclonal antibody |